A5066230062- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Colorectal and Anal Carcinomas
- Ferroptosis and cancer prognosis
- Lymphoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- 3D Printing in Biomedical Research
- X-ray Diffraction in Crystallography
- RNA modifications and cancer
- Cancer Cells and Metastasis
- Crystallization and Solubility Studies
- Advanced Breast Cancer Therapies
- Additive Manufacturing and 3D Printing Technologies
- Salivary Gland Tumors Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Molecular Biology Techniques and Applications
- Metastasis and carcinoma case studies
- Breast Lesions and Carcinomas
- Nanoplatforms for cancer theranostics
City University of Hong Kong
2023-2025
Addgene
2023-2024
Federal Almazov North-West Medical Research Centre
2022
Institute of Oncology NN Petrov
2018-2022
Research Medical Center
2022
Ministry of Health of the Russian Federation
2018-2021
Amur State Medical Academy
2015-2017
Although various metal-based compounds have exhibited excellent immunogenic cell death (ICD)-inducing properties both in vitro and vivo, the majority of these been discovered serendipitously. In this work, we successfully synthesized characterized 35 cyclometalated Au(III) complexes containing dithiocarbamate ligands, with 25 being previously unreported. Their ability to induce phagocytosis against immunologically "cold" malignant pleural mesothelioma (MPM) cells was strongly dependent on...
Abstract Triple‐negative breast cancer (TNBC) is the most aggressive subtype of cancer, characterized by an aberrant metabolic phenotype with high metastatic capacity, resulting in poor patient prognoses and low survival rates. We designed a series novel Au III cyclometalated prodrugs energy‐disrupting Type II antidiabetic drugs namely, metformin phenformin. Prodrug activation release ligand was achieved tuning fragment. The lead complex 3met 6000‐fold more cytotoxic compared to...
Objective: Immune checkpoints inhibitors are promising and wide-spread agents in anti-cancer therapy. However, despite their efficacy, these could cause cardiotoxicity, a rare but life-threatening event. In addition, there still no well-described predictive factors for the development of immune-related adverse events information on high risk groups. According to known experimental studies we hypothesized that cardiovascular diseases may increase myocardial PD-L1 expression, which be an extra...
<p>Supplementary Appendix</p>
<p>Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: primary site, stratifed by arm. C: RECIST tumor site (yellow) and nodes (purple), arm.</p>
<div>AbstractPurpose:<p>We evaluated whether indoleamine 2,3-dioxygenase (IDO1) inhibitor (IDOi) BMS986205 + PD-1 nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable head neck squamous cell carcinoma (HNSCC). We employed response-adaptive surgical timing to identify responders immunotherapy enhance their response.</p>Patients Methods:<p>Patients with HNSCC were 3:1 randomized receive or without orally daily...
<p>Supplement Figure 4: STRING Networks enlarged. The networks of B cell (A) and CAF (B) as visualized in 5.</p>
<p>Supplement Figure 3: Signature-based Biomarkers. A: Signature-Based biomarkers for HPV negative patients. B: positive ‘Primary Path Response’ refers to analysis based on the pTR at primary site alone. ‘Overall path response’ + lymph node response.</p>
<p>Supplementary Figure 2: Effect of IDO inhibitor BMS986205 on response rate and the tryptophan kynurenine pathway. A B: IDO1 gene expression levels pathway activity score, respectively, compared between baseline samples responders (R) non-responders (NR) nivolumab + nivolumab-only therapies. C: Tryptophan score post-treatment R NR - ns, *p < 0.05, **p 0.01, ***p 0.001.</p>
<p>Supplemental Appendix 1. Study protocol.</p>
<div>AbstractPurpose:<p>Treatments after anti–PD-1 therapy for patients with recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited. Blocking PI3K signaling may lead to tumor immunomodulation enhanced taxane sensitivity. This phase 2 trial evaluated dual, selective PI3Kδ/γ inhibition docetaxel in refractory HNSCC.</p>Patients Methods:<p>Patients received duvelisib (25 mg orally twice daily) (75 mg/m<sup>2</sup> IV) every 21 days....
<p>Supplemental Table 1. Overview of the multiplex immunofluorescence panel.</p>
<p>Supplemental Table 7. Correlating pre-treatment tumor immune cell parameters with outcomes (N=18).</p>
<p>Supplemental Table 5. Univariate Hazard ratio and 95% CI for Cox proportional hazard models on overall survival.</p>
<p>Supplemental Table 4. Univariate odds ratio and 95% CI for logistic regression models predictors of response.</p>
<p>Supplemental Table 6. Results of multiplex immunofluorescence profiling on tumor specimens.</p>
<p>Supplemental Table 3. Reasons for Treatment Discontinuation.</p>
<p>Supplemental Table 2. Representativeness of Study Participants.</p>
<p>Supplemental Table 4. Univariate odds ratio and 95% CI for logistic regression models predictors of response.</p>
<p>Supplemental Table 5. Univariate Hazard ratio and 95% CI for Cox proportional hazard models on overall survival.</p>
<p>Supplemental Appendix 1. Study protocol.</p>